Thermo Fisher Scientific, Inc. - TMO STOCK NEWS

Thermo Fisher Scientific (NYSE: TMO) announced a management change, with Alan Sachs transitioning to the role of chief medical officer and Karen E. Nelson appointed as chief scientific officer, effective August 2021. Sachs, who has been with the company since 2016, aims to enhance clinical strategy and support innovative product development. Nelson brings extensive experience from the J. Craig Venter Institute and a strong publication record. This leadership shift is designed to align R&D with evolving customer needs and bolster the company's commitment to advancing science.

Thermo Fisher Scientific and UC Davis announced the launch of the Center of Excellence in Clinical Metabolomics, aimed at advancing metabolomics research. This collaboration focuses on creating standard practices and protocols to enhance large cohort studies and clinical research. The center will utilize advanced Orbitrap technology for high-quality metabolic profiling and provide training for early-career scientists. Mark Stevenson emphasized the partnership's significance in refining techniques critical for clinical relevance.

Thermo Fisher Scientific (NYSE: TMO) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 9:40 a.m. EDT. Marc N. Casper, the CEO, will present virtually, with the webcast available on their website. Thermo Fisher, a leader in serving science with over $30 billion in annual revenue, supports various sectors, including life sciences and diagnostics. Their global team of over 80,000 employees provides innovative technologies and services through renowned brands.

Thermo Fisher Scientific (TMO) announced a quarterly cash dividend of $0.26 per common share, payable on July 15, 2021, to shareholders recorded by June 15, 2021. The company, a leader in serving science with over $30 billion in annual revenue, aims to support advancements in life sciences, diagnostics, and laboratory productivity. With a workforce of more than 80,000 employees, Thermo Fisher delivers innovative technologies through its renowned brands.

Thermo Fisher Scientific (NYSE:TMO) has partnered with the University of California, San Francisco (UCSF) to establish a cutting-edge cell therapy development and manufacturing facility. This 44,000-square-foot center will be located on UCSF's Mission Bay campus and is set to begin operations in 2022. The facility will provide clinical and commercial cGMP manufacturing services, enhancing access to Thermo Fisher's extensive Cell Therapy Systems portfolio. The collaboration aims to accelerate the development of innovative cell-based therapies, ultimately improving patient access to vital treatments.

Thermo Fisher Scientific will present at the BofA Securities 2021 Health Care Conference on May 12, 2021, at 8:45 a.m. EDT. The presentation will be virtual, led by Marc N. Casper, the company’s chairman and CEO. Investors can access the webcast on the company's website. Thermo Fisher, a leader in serving science, reported annual revenues exceeding $30 billion and employs over 80,000 people globally, offering innovative technologies and services across multiple brands.

Thermo Fisher Scientific (TMO) reported strong Q1 2021 results, with revenue up 59% to $9.91 billion and GAAP diluted EPS soaring 198% to $5.88. Adjusted EPS rose 145% to $7.21. The company significantly contributed to COVID-19 responses, enhancing vaccine production and testing capacities. Key product launches included innovative analytical instruments and bioproduction technologies. Strong capital deployment actions included a $2 billion stock repurchase and an 18% dividend increase. The company announced plans to acquire PPD, Inc. for $17.4 billion, further solidifying its market position.

Thermo Fisher Scientific has announced its acquisition of PPD for $47.50 per share, totaling $17.4 billion plus $3.5 billion in net debt. This deal represents a 24% premium to PPD's stock price as of April 13, 2021. PPD, a leader in the $50 billion clinical research services industry, generated $4.7 billion in revenue in 2020. The transaction is expected to close by the end of 2021 and will enhance Thermo Fisher's services to the pharma and biotech sectors, with projected cost synergies of $125 million by year three.

Thermo Fisher Scientific Inc. (NYSE:TMO) has received Emergency Use Authorization (EUA) from the FDA for its Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit. This system allows laboratories to conduct up to 8,000 PCR tests daily with minimal staffing. The Amplitude Solution combines Thermo Fisher's technologies and is already implemented in labs globally, including Europe and Japan. Although COVID-19 cases are decreasing, demand for routine testing remains, reinforcing the system's relevance. The solution is aimed at scaling testing capacity amidst ongoing pandemic challenges.